Samsung Epis Holdings Co Ltd
Samsung Epis Holdings Co Ltd is engaged in the pharmaceuticals and medical research industry, focusing on biotechnology and medical research.
Business. Samsung Epis Holdings Co Ltd (0126Z0.KS) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily engaged in pharmaceuticals and medical research activities. It is listed on the Korea Exchange (KRX). Specific details regarding operating segments and geographic presence are not available.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Samsung Epis Holdings Co Ltd (0126Z0.KS) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily engaged in pharmaceuticals and medical research activities. It is listed on the Korea Exchange (KRX). Specific details regarding operating segments and geographic presence are not available.
Samsung Epis Holdings Co Ltd has a basic and diluted share count of 24,883,049 shares outstanding, indicating no dilution from potential share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's valuation snapshot is not available, which limits the ability to assess its relative value compared to industry peers.
Profitability and returns data are not available for Samsung Epis Holdings Co Ltd, making it difficult to compare its performance against the preferred metrics of the Biotechnology & Medical Research industry. Without access to profitability ratios such as ROIC or EBITDA margins, it is not possible to determine whether the company is outperforming or underperforming the industry median.
Segment and geographic exposure data are not disclosed in the available source documents, which limits the ability to assess the company's revenue concentration or geographic diversification. This lack of transparency could pose a risk to investors who rely on such information to evaluate the company's exposure to regional economic or regulatory changes.
Growth trajectory data is not available for Samsung Epis Holdings Co Ltd, as no outlook or revenue history is provided in the source documents. Analysts have provided a mean price target of 695,000 KRW, with a median of 695,000 KRW, and a range from 620,000 KRW to 770,000 KRW. The mean recommendation is 2.33, indicating a generally positive outlook, with two buy and one hold recommendation.
The company is currently assessed as having low dilution risk, with no near-term pressure from potential share issuance. However, the absence of detailed risk assessment data and the lack of balance-sheet inputs make it difficult to fully evaluate the company's financial health and risk profile.
Recent events, including filings and transcripts, are not disclosed in the available source documents, which limits the ability to assess the company's recent performance or strategic direction.
- Samsung Epis Holdings Co Ltd has no dilution from potential share issuance, with basic and diluted shares outstanding being equal.
- Analysts have provided a generally positive outlook, with a mean recommendation of 2.33 and a price target range of 620,000 KRW to 770,000 KRW.
- The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
- Profitability and returns data are not available, making it difficult to compare the company's performance against industry peers.
- Segment and geographic exposure data are not disclosed, limiting the ability to assess the company's revenue concentration or geographic diversification.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue KRW 251.69B; Operating income -KRW 68.53B.
- ▍Revenue KRW 251.69B
- ▍Operating income -KRW 68.53B
- ▍Net margin -12.5%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 12 879,07 |
| Revenue | —no estimate | —no estimate | 1,84T KRW |
| Operating income | —no estimate | —no estimate | 328,0B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Samsung Epis Holdings Co Ltd Market data — financials · 2026-05-26
- Samsung Epis Holdings Co Ltd Market data — analyst estimates · 2026-05-26